Related Experiment Video
Updated: Mar 22, 2026
20:23
A Lectin HPLC Method to Enrich Selectively-glycosylated Peptides from Complex Biological Samples
Published on: October 1, 2009
16.6K
Identification of Lectins from Metastatic Cancer Cells through Magnetic Glyconanoparticles
Herbert W Kavunja1, Patricia G Voss2, John L Wang2
1Department of Chemistry, Chemistry Building, Room 426, 578 S. Shaw Lane, Michigan State University, East Lansing, MI 48824 (USA).
Israel Journal of Chemistry
|April 26, 2016
Summary
Researchers identified specific galactose-binding proteins, including Sfrs1, in highly metastatic melanoma cells using magnetic glyconanoparticles. This discovery aids in understanding cancer cell binding properties and identifying new therapeutic targets.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Cancer cells exhibit distinct carbohydrate-binding properties.
- Metastatic melanoma cells (B16F10) show stronger binding to galacto-side nanoparticles than less metastatic cells (B16F1).
Purpose of the Study:
- To isolate and characterize endogenous galactose-binding proteins from metastatic melanoma cells.
- To understand the role of specific lectins in cancer cell binding properties.
Main Methods:
- Utilized magnetic glyconanoparticles functionalized with galactose.
- Employed magnet-mediated separation for lectin isolation.
- Applied Western blot and mass spectrometry for protein identification.
Main Results:
- Identified arginine/serine rich splicing factor Sfrs1 as a galactose-selective lectin overexpressed in B16F10 cells.
- Found higher amounts of galectin-3 in B16F10 cells compared to B16F1 cells.
- Demonstrated superior efficiency of glyconanoparticles over microparticles for lectin isolation from complex samples and live cells.
Conclusions:
- Magnetic glyconanoparticles are effective tools for discovering endogenous lectins and their binding partners.
- Sfrs1 and galectin-3 are key galactose-binding proteins implicated in melanoma cell behavior.
- This approach facilitates lectin discovery without prior protein identification, advancing cancer cell binding studies.
